4D Molecular Therapeutics (FDMT) closed at $12.99 on November 11, 2026, up 4.3% from the previous close, on volume of 811,191 shares (30-day average 957,537).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Diagonal Call Spread | 20-Nov-26 : 15-Jan-2712 : 15 C | 200 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
4DMT to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
4DMT Announces New Employment Inducement Grants
Globe Newswire (Fri, 16-Oct 4:05 PM ET)
FDMT Sets October 21, 2026 Investor Day Spotlighting Phase 3 Retina Program 4D-150
Market Chameleon (Mon, 5-Oct 7:53 AM ET)
4DMT to Host Investor Day on October 21, 2026
Globe Newswire (Mon, 5-Oct 8:00 AM ET)
Globe Newswire (Mon, 28-Sep 8:00 AM ET)
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
FDMT Secures $100 Million in Fresh Funding: New Offering Expands Clinical Ambitions
Market Chameleon (Thu, 6-Nov 3:05 AM ET)
Market Chameleon (Fri, 31-Oct 3:07 AM ET)
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.
As of November 12, 2026, FDMT stock price declined to $12.33 with 81,254 million shares trading.
FDMT has a beta of 0.95, meaning it tends to be less sensitive to market movements. FDMT has a correlation of 0.03 to the broad based SPY ETF.
FDMT has a market cap of $681.16 million. This is considered a Small Cap stock.
Last quarter 4D Molecular Therapeutics reported $4 million in Revenue and -$1.04 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.02.
In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.
The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
FDMT has outperformed the market in the last year with a return of +14.2%, while the SPY ETF gained +12.0%. In the last 3 month period, FDMT beat the market returning +7.5%, while SPY returned -1.5%. However, in the most recent 2 weeks FDMT has underperformed the stock market by returning -4.6%, while SPY returned -2.0%.
FDMT support price is $12.25 and resistance is $13.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.
